Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa IncfiledCriticalBioverativ Usa Inc
Priority claimed from PCT/US2018/022462external-prioritypatent/WO2018170145A1/en
Publication of TN2019000238A1publicationCriticalpatent/TN2019000238A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
The present disclosure provides methods of treating a complement-mediated disease or disorder in an individual, and methods of inhibiting activation of complement component C4 in an individual in need thereof. The methods comprise administering to the individual an anti-C1s antibody. The methods also comprise administering an anti-C1s antibody in a fixed dose, e.g., 5.5 g, 6.5 g, or 7.5 g. The methods also comprise administering an effective dose of an anti-C1s antibody to the individual to achieve a minimum serum level of anti-C1s antibody for therapeutic effect.
TNP/2019/000238A2017-08-312018-03-14Methods for treating complement-mediated diseases and disorders
TN2019000238A1
(en)